Global Medical Directory is part of the Global Exhibitions Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.



Many treatments for early-stage cancer involve ‘sentinel lymph node biopsy’, or SLNB. This method, which identifies the lymph nodes with the highest potential for harbouring metastases, helps to determine the nodal stage of the cancer and make informed decisions for surgery and subsequent treatment.

Standard SLNB uses radioisotopes for sentinel node localisation. We offer an effective clinical solution that uses safe magnetic fields instead. This eliminates concerns related to the safety, workflow and availability associated with ionising radiation. Best practice SLNB is now possible everywhere, with no time restrictions.

Our system consists of the Sentimag® probe and the Sienna+®magnetic tracer. First, the tracer is injected into the interstitial tissue to provide a traceable signal. Next, using the Sentimag® probe, you locate the sentinel lymph nodes to determine how far the cancer has spread.


Sienna+ – An effective clinical solution

Perform best practice SLNB in any clinical setting

Eliminate issues with radioactive materials; reach equivalent clinical outcomes

As a surgeon, organise and manage the SLNB procedure to suit your needs

Inject the tracer at the best moment, up to seven days in advance

No evidence of anaphylaxis with interstitial tracer injection

Sentimag® and Sienna+® are CE-approved for SLN localisation

Connect with this vendor - Learn about this product
Sentimag / Sienna+ – Magnetic lymph node localisation